Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Auro Pharma’s Andhra Pradesh facility gets 3 USFDA observations     Back
(08 Apr 2024)

The new injectable facility of Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company), situated at Parawada Mandal, Anakapalli district, Andhra Pradesh, has recently started the commercial operations.

The United States Food and Drug Administration (USFDA) inspected the facility from 28 March 2024 to 5 April 2024.

The inspection closed with three observations. The observations are procedural in nature and will be responded to within the stipulated time, the company stated in the press release.

On 6 April 2024, the company informed that an accident occurred near Vacuum Tray Dryer (VTD) area at Unit 6 of Apitoria Pharma (wholly owned subsidiary of the company), situated at Parawada, Anakapalli district, Andhra Pradesh. The firm said that there was one casualty due to the accident.

Further, the company added the unit continues its normal operations.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The drug maker reported 90.58% jump in consolidated net profit to Rs 936.29 crore on 13.82% rise in revenue from operations to Rs 7,271.23 crore in Q3 FY24 over Q3 FY23.

The scrip shed 0.19% to end at Rs 1,121 on the BSE.

Top